article thumbnail

IMV: Nuclear medicine procedure volumes decrease

AuntMinnie

Total nuclear medicine patient study volumes decreased by 5.7% between 2021 and 2023, with a 10.7% Two-year compound annual growth rates (CAGR) between 2021 and 2023 show an overall average 2.9% Specifically considering cardiovascular nuclear medicine procedures, total procedures have decreased by 7.1%

article thumbnail

IMV: PET scan volumes continue to grow

AuntMinnie

In 2023 compared with 2022, the total volume of positron emission tomography (PET) scans increased 10.2% In 2023, the average number of PET scans per fixed PET site (versus mobile PET) increased 6.7% from 1,401 estimated PET scans per system in 2022 to 1,495 in 2023. Davin Korstjens. physicians reading PET scans per site.

PET Scan 115
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

SNMMI Elects Cathy Sue Cutler, PhD, FSNMMI, as President at 2024 Annual Meeting

Imaging Technology

milla1cf Wed, 06/12/2024 - 21:58 June 12, 2024 — Cathy Sue Cutler, PhD, FSNMMI , chair of the Isotope Research and Production Department at Brookhaven National Laboratory in Upton, New York, has been named as president for the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

article thumbnail

Cardinal Health Highlights Nuctrac Theranostic Module, Theranostics Readiness at SNMMI 2023

Imaging Technology

milla1cf Fri, 06/23/2023 - 22:04 June 23, 2023 — Cardinal Health Nuclear & Precision Health Solutions (NPHS) (Booth #2041) will feature information on radiotherapies and theranostics readiness at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2023 Annual Meeting.

article thumbnail

First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

Imaging Technology

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use. Lancet Oncology 2023; 24(3): e133-e143.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

article thumbnail

UCSF's Henry VanBrocklin Receives the Prestigious Aebersold Award at SNMMI

UCSF Biomedical Imaging

Congratulations to Henry VanBrocklin, PhD, FSNMMI, FSRS, recipient of the 2023 Paul C. Dr. VanBrocklin is a professor in the Department of Radiology and Biomedical Imaging and director of the Radiopharmaceutical Research Program in the Center for Molecular and Functional Imaging at the University of California, San Francisco (UCSF).